Compare CGEM & GHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | GHM |
|---|---|---|
| Founded | 2016 | 1936 |
| Country | United States | United States |
| Employees | N/A | 732 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 1.3B |
| IPO Year | 2020 | 1994 |
| Metric | CGEM | GHM |
|---|---|---|
| Price | $17.55 | $110.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $30.13 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 1.3M | 271.8K |
| Earning Date | 05-11-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.90 |
| EPS | N/A | ★ 1.12 |
| Revenue | N/A | ★ $245,293,000.00 |
| Revenue This Year | N/A | $14.54 |
| Revenue Next Year | $5.20 | $18.23 |
| P/E Ratio | ★ N/A | $96.35 |
| Revenue Growth | N/A | ★ 16.86 |
| 52 Week Low | $5.68 | $46.08 |
| 52 Week High | $17.40 | $119.04 |
| Indicator | CGEM | GHM |
|---|---|---|
| Relative Strength Index (RSI) | 67.84 | 58.03 |
| Support Level | $11.87 | $88.46 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.34 | 7.43 |
| MACD | 0.39 | 0.57 |
| Stochastic Oscillator | 93.97 | 72.23 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Graham Corp designs and manufactures mission-critical fluid, power, heat transfer, vacuum, and mixing technologies for the Defense, Energy & Process, and Space industries. In Defense, its equipment is used in nuclear and non-nuclear propulsion, power, fluid transfer, thermal management, and mixing systems. In Energy & Process industries, it supplies equipment for vacuum, heat transfer, mixing, and fluid transfer applications used in oil refining, chemical facilities, fertilizers, ethylene, methanol, energetics, food & beverage, medical, and alternative energy applications such as hydrogen and geothermal processes. In the Space industry, its equipment is used in propulsion, power, thermal management, mixing, and life support systems. It operates in the United States and other countries.